• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novo Nordisk joins Allergan in pledge to limit price hikes

December 6, 2016 By Sarah Faulkner

Novo Nordisk joins Allergan in pledge to limit price hikesNovo Nordisk (NYSE:NVO) president Jakob Riis said this week that the company will limit annual price hikes of its products’ list prices to single-digit percentages, joining Allergan (NYSE:AGN) CEO Brent Saunders who released a “social contract” 3 months ago with the same goal.

“We hear from more and more people living with diabetes about the challenges they face affording healthcare, including the medicines we make. We take this issue seriously and have been thinking about what we can do to better support patients,” Riis wrote in a statement. “This has become a responsibility that needs to be shared among all those involved in healthcare and we’re going to do our part.”

Saunders has been vocal about the need for the pharmaceutical industry to self-regulate. In a blog posted to the company’s site last week, he wrote that other company’s should join the effort to promise patients access to affordable medicines. “The biopharmaceutical industry does have a social contract with patients. Now is the time to make good on that contract by taking self-regulating action,” Saunders wrote. “Take your own stand and implement your form of a social contract.  Limit your price increases before we all face the impact of government regulation that stifles innovation and patient care.”

The company pledges come at a time when drug pricing is at the forefront of public discussion regarding healthcare. The industry’s pricing problems were highlighted last year when Turing Pharmaceuticals raised the price of its malaria drug Daraprim from $13.50 to $750 a pill. This year, Mylan (NSDQ:MYL) has been the poster-child for industry greed for many politicians, after reports showed that the company raised the price of its EpiPen device 500% since it acquired the product in 2007.

Company executives, including Mylan CEO Heather Bresch, have maintained that the overall pricing system isn’t structured for consumer engagement and encourages price hikes. In his statement, Riis said that Novo has raised list prices to keep up with changes to the health care system and inflation. But, he argued that the price hikes have not kept up with rising rebates and discounts that drugmakers pay to pharmacy benefit managers to better placement on preferred coverage lists.

“As the rebates, discounts and price concessions got steeper, we were losing considerable revenue – revenue we use for R&D, sales and marketing, education, disease awareness activities and medical information support.  So, we would continue to increase the list in an attempt to offset the increased rebates, discounts and price concessions to maintain a profitable and sustainable business,” he wrote.

Riis also said that high deductible health plans “are becoming a greater part of the affordability issue,” since consumers take on more out-of-pocket costs.

“As a leader in diabetes care, we recognize patients need more. We are poised to do more, but can’t do it alone,” Riis wrote. “We need a partnership approach involving PBMs, insurance companies, employers, patient organizations and policy makers – to help find sustainable solutions.”

Filed Under: Diabetes, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Mylan, Novo Nordisk

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS